Literature DB >> 12787066

Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease.

Makoto Hashimoto1, Takato Takenouchi, Edward Rockenstein, Eliezer Masliah.   

Abstract

alpha-Synuclein accumulation plays an important role in the pathogenesis of Lewy body disease (LBD) and Parkinson's disease (PD). Although the mechanisms are not yet clear, it is possible that dysregulation of the extracellular signal-regulated kinase (ERK) might play a role. As caveolins form scaffolds onto which signaling molecules such as ERK can assemble, we propose that signaling alterations associated with alpha-synuclein accumulation and neurodegeneration, might be mediated via caveolae. Therefore, the objective of the present study was to investigate the potential contribution of alterations in the caveolar system in mediating alpha-synuclein effects on the ERK signaling pathway. For this, synuclein-transfected B103 neuroblastoma cells were used as a model system. In this cell line, caveolin-1 expression was up-regulated, whereas, ERK was down-regulated. ERK was weakly but consistently co-immunoprecipitated with alpha-synuclein but caveolin-1 did not co-immunoprecipitate with alpha-synuclein. Moreover, treatment of alpha-synuclein- overexpressing cells with caveolin-1 antisense oligonucleotides resulted in stimulation of ERK activity, with amelioration of the neuritic alterations. Transduction of alpha-synuclein-overexpressing cells, with an adenoviral vector directing the expression of ERK, resulted in suppression of caveolin-1 expression and re-establishment of the normal patterns of neurite outgrowth. These results suggest that alpha-synuclein may also interfere with ERK signaling by dysregulating caveolin-1 expression. Thus, the caveolin-1/ERK pathway could be a therapeutic target for the alpha-synuclein-related neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12787066     DOI: 10.1046/j.1471-4159.2003.01791.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  30 in total

Review 1.  Oxidative neuronal injury. The dark side of ERK1/2.

Authors:  Charleen T Chu; David J Levinthal; Scott M Kulich; Elisabeth M Chalovich; Donald B DeFranco
Journal:  Eur J Biochem       Date:  2004-06

Review 2.  Heptaspanning membrane receptors and cytoskeletal/scaffolding proteins: focus on adenosine, dopamine, and metabotropic glutamate receptor function.

Authors:  Francisco Ciruela; Laia Canela; Javier Burgueño; Ana Soriguera; Nuria Cabello; Enric I Canela; Vicent Casadó; Antonio Cortés; Josefa Mallol; Amina S Woods; Sergi Ferré; Carmen Lluis; Rafael Franco
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  FTY720-Mitoxy reduces toxicity associated with MSA-like α-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures.

Authors:  Javier Vargas-Medrano; Ismael Segura-Ulate; Barbara Yang; Ramesh Chinnasamy; Jeffrey B Arterburn; Ruth G Perez
Journal:  Neuropharmacology       Date:  2019-07-07       Impact factor: 5.250

4.  α-Synuclein protects neurons from apoptosis downstream of free-radical production through modulation of the MAPK signalling pathway.

Authors:  Ruth E J Musgrove; Anna E King; Tracey C Dickson
Journal:  Neurotox Res       Date:  2012-08-31       Impact factor: 3.911

Review 5.  Genetics of primary open angle glaucoma.

Authors:  Mitsuko Takamoto; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-11-21       Impact factor: 2.447

6.  Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.

Authors:  Leslie Crews; Brian Spencer; Paula Desplats; Christina Patrick; Amy Paulino; Edward Rockenstein; Lawrence Hansen; Anthony Adame; Douglas Galasko; Eliezer Masliah
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

7.  Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.

Authors:  Haiyan Lou; Susana E Montoya; Tshianda N M Alerte; Jian Wang; Jianjun Wu; Xiangmin Peng; Chang-Sook Hong; Emily E Friedrich; Samantha A Mader; Courtney J Pedersen; Brian S Marcus; Alison L McCormack; Donato A Di Monte; S Colette Daubner; Ruth G Perez
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

Review 8.  Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.

Authors:  Vladimir N Uversky; David Eliezer
Journal:  Curr Protein Pept Sci       Date:  2009-10       Impact factor: 3.272

9.  Parkinson's disease: genetics and beyond.

Authors:  N N Inamdar; D K Arulmozhi; A Tandon; S L Bodhankar
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

10.  Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells.

Authors:  Monica Bari; Sergio Oddi; Chiara De Simone; Paola Spagnolo; Valeria Gasperi; Natalia Battista; Diego Centonze; Mauro Maccarrone
Journal:  Neuropharmacology       Date:  2007-07-20       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.